Target delivery of small interfering RNAs with Vitamin E-coupled nanoparticles for treating hepatitis C

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Duan, Liang ^a   Yan, Yan ^a   Liu, Jingyi ^a   Wang, Bo ^a   Li, Pu ^a   Hu, Qin ^a   Chen, Weixian ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIVIRUS AGENT; DRUG CARRIER; LIPOSOME; NANOPARTICLE; SMALL INTERFERING RNA;

ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DISEASE MODEL; HEPATITIS C; HUMAN; LIVER CELL; METABOLISM;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HEPATITIS C; HEPATOCYTES; HUMANS; LIPOSOMES; MICE, INBRED BALB C; NANOPARTICLES; RNA, SMALL INTERFERING; VITAMIN E;

EID: 84964671914     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24867     Document Type: Article

References (54)

1. Kohli, A., Shaffer, A., Sherman, A., Kottilil, S. Treatment of hepatitis C: a systematic review. Jama. 312, 631-640 (2014).
2. Gonzalez-Reimers, E. et al. Liver steatosis in hepatitis C patients. World journal of hepatology. 7, 1337-1346 (2015).
3. Jeffers, L. Hepatocellular carcinoma: an emerging problem with hepatitis C. Journal of the National Medical Association. 92, 369-371 (2000).
4. Webster, D. P., Klenerman, P., Dusheiko, G. M. Hepatitis C. Lancet. 385, 1124-1135 (2015).
5. Watashi, K., Shimotohno, K. The roles of hepatitis C virus proteins in modulation of cellular functions: a novel action mechanism of the HCV core protein on gene regulation by nuclear hormone receptors. Cancer science. 94, 937-943 (2003).
6. Suzuki, R., Suzuki, T., Ishii, K., Matsuura, Y., Miyamura, T. Processing and functions of Hepatitis C virus proteins. Intervirology. 42, 145-152 (1999).
7. Okuda, M. et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 122, 366-375 (2002).
8. Kao, C. C., Yi, G., Huang, H. C. The core of hepatitis C virus pathogenesis. Current opinion in virology. 17, 66-73 (2016).
9. Kaufmann, K. B., Buning, H., Galy, A., Schambach, A., Grez, M. Gene therapy on the move. EMBO molecular medicine. 5, 1642-1661 (2013).
10. Dorsett, Y., Tuschl, T. siRNAs: applications in functional genomics and potential as therapeutics. Nature reviews. Drug discovery. 3, 318-329 (2004).
11. Novina, C. D. et al. siRNA-directed inhibition of HIV-1 infection. Nature medicine. 8, 681-686, doi: 10.1038/nm725 (2002).
12. Ahmed, O., Kruhn, A., Lage, H. Delivery of siRNAs to cancer cells via bacteria. Methods in molecular biology. 1218, 117-129 (2015).
13. Xu, Z. et al. Inhibition of expression of rna polymerase with small interfering RNAs targeting a conserved motif in the respective viral genes in viruses of the family Flaviviridae. Acta virologica. 51, 195-201 (2007).
14. Kapadia, S. B., Brideau-Andersen, A., Chisari, F. V. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proceedings of the National Academy of Sciences of the United States of America. 100, 2014-2018 (2003).
15. Prabhu, R. et al. Small interfering RNA effectively inhibits protein expression and negative strand RNA synthesis from a full-length hepatitis C virus clone. Journal of medical virology. 76, 511-519 (2005).
16. Xing, X. K., He, J. L., Chen, Z. [Inhibition of hepatitis C virus replication by small interfering RNA in cells infected by HCV]. Zhejiang da xue xue bao. Yi xue ban= Journal of Zhejiang University. Medical sciences. 40, 582-587 (2011).
17. Khaliq, S. et al. RNAi as a new therapeutic strategy against HCV. Biotechnology advances. 28, 27-34 (2010).
18. Bandiera, S., Pfeffer, S., Baumert, T. F., Zeisel, M. B. miR-122-a key factor and therapeutic target in liver disease. Journal of hepatology. 62, 448-457 (2015).
19. Hildebrandt-Eriksen, E. S. et al. A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. Nucleic acid therapeutics. 22, 152-161 (2012).
20. Thomas, C. E., Ehrhardt, A., Kay, M. A. Progress and problems with the use of viral vectors for gene therapy. Nature reviews. Genetics. 4, 346-358 (2003).
21. Wiethoff, C. M., Koe, J. G., Koe, G. S., Middaugh, C. R. Compositional effects of cationic lipid/DNA delivery systems on transgene expression in cell culture. Journal of pharmaceutical sciences. 93, 108-123 (2004).
22. Mintzer, M. A., Simanek, E. E. Nonviral vectors for gene delivery. Chemical reviews. 109, 259-302 (2009).
23. Sen, J., Chaudhuri, A. Design, syntheses, and transfection biology of novel non-cholesterol-based guanidinylated cationic lipids. Journal of medicinal chemistry. 48, 812-820 (2005).
24. Lv, H., Zhang, S., Wang, B., Cui, S., Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. Journal of controlled release official journal of the Controlled Release Society. 114, 100-109 (2006).
25. Rigotti, A. Absorption, transport, and tissue delivery of vitamin E. Molecular aspects of medicine. 28, 423-436 (2007).
26. Miyazaki, H., Takitani, K., Koh, M., Yoden, A., Tamai, H. The alpha-tocopherol status and expression of alpha-tocopherol-related proteins in methionine-choline deficient rats treated with vitamin E. Journal of clinical biochemistry and nutrition. 54, 190-197 (2014).
27. Li, L. et al. Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B. Virology journal. 10, 214 (2013).
28. Walther, W., Stein, U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs. 60, 249-271 (2000).
29. Pezzoli, D., Kajaste-Rudnitski, A., Chiesa, R., Candiani, G. Lipid-based nanoparticles as nonviral gene delivery vectors. Methods in molecular biology. 1025, 269-279 (2013).
30. Bozzuto, G., Molinari, A. Liposomes as nanomedical devices. International journal of nanomedicine. 10, 975-999 (2015).
31. Chen, J., Sun, X., Yu, Z., Gao, J., Liang, W. Influence of lipid components on gene delivery by polycation liposomes: Transfection efficiency, intracellular kinetics and in vivo tumor inhibition. International journal of pharmaceutics. 422, 510-515 (2012).
32. Ma, Z. et al. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochemical and biophysical research communications. 330, 755-759 (2005).
33. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 432, 173-178 (2004).
34. Wu, Y. et al. Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell host & microbe. 5, 84-94 (2009).
35. Sato, Y. et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nature biotechnology. 26, 431-442 (2008).
36. Li, Y., Liu, F., Ding, F., Chen, P., Tang, M. Inhibition of liver fibrosis using vitamin A-coupled liposomes to deliver matrix metalloproteinase-2 siRNA in vitro. Molecular medicine reports. 12, 3453-3461 (2015).
37. Nishina, K. et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Molecular therapy: the journal of the American Society of Gene Therapy. 16, 734-740 (2008).
38. Yao, T. et al. Inhibition of carbon tetrachloride-induced liver injury by liposomes containing vitamin E. The American journal of physiology. 267, G476-484 (1994).
39. Pekmezci, D. Vitamin E and immunity. Vitamins and hormones. 86, 179-215 (2011).
40. Kappus, H., Diplock, A. T. Tolerance and safety of vitamin E: a toxicological position report. Free radical biology & medicine. 13, 55-74 (1992).
41. Kato, Y. et al. Blood clearance and tissue distribution of various formulations of alpha-tocopherol injection after intravenous administration. Chemical & pharmaceutical bulletin. 41, 599-604 (1993).
42. Suda, T., Liu, D. Hydrodynamic gene delivery: its principles and applications. Molecular therapy: the journal of the American Society of Gene Therapy. 15, 2063-2069 (2007).
43. Sawyer, G. J. et al. Hydrodynamic gene delivery to the liver: theoretical and practical issues for clinical application. Current gene therapy. 9, 128-135 (2009).
44. Watanabe, T. et al. Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome. Journal of hepatology. 47, 744-750 (2007).
45. Kim, S. I. et al. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. Journal of hepatology. 50, 479-488 (2009).
46. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature biotechnology. 25, 1149-1157 (2007).
47. Jerkovic, L. et al. Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression. Journal of proteome research. 4, 889-899 (2005).
48. Liu, H., Ren, H., Spear, B. T. The mouse alpha-albumin (afamin) promoter is differentially regulated by hepatocyte nuclear factor 1alpha and hepatocyte nuclear factor 1beta. DNA and cell biology. 30, 137-147 (2011).
49. Gao, X., Wilde, P. E., Lichtenstein, A. H., Bermudez, O. I., Tucker, K. L. The maximal amount of dietary alpha-tocopherol intake in U.S. adults (NHANES 2001-2002). The Journal of nutrition. 136, 1021-1026 (2006).
50. Robbins, M. et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Human gene therapy. 19, 991-999 (2008).
51. Judge, A. D., Bola, G., Lee, A. C., MacLachlan, I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Molecular therapy: the journal of the American Society of Gene Therapy. 13, 494-505 (2006).
52. Date, T. et al. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. The Journal of biological chemistry. 279, 22371-22376 (2004).
53. Zhang, X. et al. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells. Biomaterials. 35, 6130-6141 (2014).
54. Chen, W. et al. HCV core protein interacts with Dicer to antagonize RNA silencing. Virus research. 133, 250-258 (2008).